Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders.

ABSTRACT: Background: Rare cancers occur with an incidence of no more than six cases per 100,000 people according to the definition used by the Surveillance of Rare Cancers in Europe project. For a variety of reasons (low prevalence, cytotoxicity), it is challenging to perform the necessary clinical studies to investigate the safety and efficacy of investigational medicines against such rare malignancies, reformulating even at the earliest stages of the drug development process. This article investigates the differences between phase I rare cancer trials performed in commercial (companies) and non-commercial settings (academic hospitals). Materials and Methods: The differences were explored through the conduct of semi-structured interviews with three different stakeholder groups: repre

SUBMITTER: Dooms M 

PROVIDER: S-EPMC9108391 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature